---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-008331"
form_type: "8-K"
ticker: "IDXX"
cik: "0000874716"
company_name: "IDEXX LABORATORIES INC /DE"
filed_at: "2025-02-03T23:59:59+00:00"
generated_at: "2026-05-27T04:26:17.656719+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# IDEXX Q4 revenue $954M (+6% YoY), EPS $2.62; guides 2025 rev $4.06-$4.17B, EPS $11.74-$12.24

## Summary
- Q4 revenue $954M (+6% reported and organic); CAG Diagnostics recurring revenue +7% organic.
- Q4 EPS $2.62 (+13% as reported, +10% comparable); full year EPS $10.67 (+12% comparable).
- 2025 revenue guidance $4.055-$4.170B (+4-7% reported, +6-9% organic); EPS $11.74-$12.24 (+10-15% reported).
- Expects ~$1.5B in share repurchases in 2025 (~4% of market cap), subject to market conditions.
- 2024 full year revenue $3.898B (+6% as reported and organic); targets 200-250 bps operating margin improvement in 2025.

## SEC filing metadata
- accession: 0001104659-25-008331
- form_type: 8-K
- ticker: IDXX
- cik: 0000874716
- company_name: IDEXX LABORATORIES INC /DE
- filed_at: 2025-02-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/874716/000110465925008331/0001104659-25-008331-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/874716/000110465925008331/tm255269d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-008331
- JSON: https://secwatch.observer/filing/0001104659-25-008331.json
- Plain text: https://secwatch.observer/filing/0001104659-25-008331.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.